Tecfidera Launch Ensures Multiyear Dominance Biogen's strategy has its roots in the 2003 merger of Biogen (MS drug Avonex) and Idec (cancer drug Rituxan). Rituxan's market penetration is already high, ...

Biogen Idec’s multiple sclerosis drug Avonex can cause severe liver damage, U.S. regulatory officials and the company warned Wednesday, the latest in a series of blows to MS patients. Subscribe to ...

Denver, CO – June 2, 2008 – Results from an analysis assessing the differences in health benefits costs (HBCs) and lost time among employees suffering from multiple sclerosis (MS) being treated with ...

Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, ...

Biogen Idec BIIB today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like ...

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" W. Bonney ...

Just as Biogen’s multiple sclerosis franchise is under serious threat from generics and new competition, the company has decided to pay top dollar to settle a long-running kickback lawsuit centered on ...

BOSTON (CBS.MW) -- Biogen said Thursday it expects revenue to double to $2 billion by 2005, but the biotech firm also cautioned that earnings next year could be flat with this year's level. Speaking ...

As expected, the FDA granted Biogen Inc. a new label indication for the multiple sclerosis drug Avonex (interferon beta-1a), allowing it to be prescribed for treatment of patients after the first MS ...

Biogen Idec Inc. soundly beat earnings estimates for the quarter by more than 16 percent. The company reported adjusted net income of $1.82 per share and Wall Street was looking for $1.56 per share.